Почетна › Trostruko negativni rak dojke › Тексас
Kliničke studije za Trostruko negativni rak dojke u državi Тексас
59 studija za Trostruko negativni rak dojke traži učesnike na lokacijama u državi Тексас.
Gradovi u državi Тексас
- Houston42 студија
- San Antonio24 студија
- Dallas18 студија
- Austin12 студија
- Fort Worth7 студија
- Irving4 студија
- League City3 студија
- El Paso3 студија
- Lewisville3 студија
Zvanični tekst studije (na engleskom)
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- University of Texas Medical Branch, Galveston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT03606967Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
- UT MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT05111561A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- NEXT Austin, Austin
- START Center for Clinical Research, Fort Worth
- University of Texas MD Anderson Cancer Center, Houston
- и још 2
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06270706A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Texas Oncology - DFW ( Site 8007), Dallas
- Texas Oncology - West Texas ( Site 8004), El Paso
- Kelsey-Seybold Clinic - North Houston Campus ( Site 0096), Houston
- и још 2
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06841354A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Texas Oncology - DFW ( Site 8009), Dallas
- UT Southwestern ( Site 0092), Dallas
- Texas Oncology - Northeast Texas ( Site 8002), Flower Mound
- и још 6
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06966700A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- NEXT Texas LLC - Austin, Austin
- START Dallas Fort Worth, LLC, Fort Worth
- MD Anderson, Houston
- и још 4
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07503808Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
- START San Antonio, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Жене · Ажурирано 9. 11. 2026. · NCT07652242A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- NEXT Oncology, Austin
- UT Southwestern, Dallas
Тражи се учесникФаза 1
Узраст 19 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06586957A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07029399A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center - Conroe, Conroe
- The University of Texas - M.D. Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
- и још 3
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07318805Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Hendrick Medical Center ( Site 0117), Abilene
- Harrington Cancer Center ( Site 0061), Amarillo
- Texas Oncology - DFW ( Site 8000), Dallas
- и још 9
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06393374A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START), San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06465069Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Texas Oncology, Austin
- Texas Oncology, El Paso
- MD Anderson Cancer Center, Houston
- и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05633654Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Texas Oncology, Abilene
- Texas Oncology - Central / South Texas, Austin
- Mary Crowley Cancer Research, Dallas
- и још 3
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05579366A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- The University of Texas - MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06400472Study of XB010 in Subjects With Solid Tumors
- NEXT Austin, Austin
- Baylor University Medical Center, Dallas
- University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT06545331A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT07705334Intratumoral N17350 in Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 21. 10. 2026. · NCT07339176SMP-3124LP in Adults With Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 15. 10. 2026. · NCT06526819Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- MD Anderson Cancer Center /ID# 255131, Houston
- Univ Texas HSC San Antonio /ID# 257708, San Antonio
- South Texas Accelerated Research Therapeutics /ID# 260404, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT06084481First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06799065Neratinib in Combination With Ruxolitinib in Patients With mTNBC
- Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas
Тражи се учесникРана фаза 1
Узраст 18 и старији · Жене · Ажурирано 13. 10. 2026. · NCT06008275A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, San Antonio
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT07749586A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, Houston
- Research Site, San Antonio
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07115043The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- New Experimental Therapeutics - NEXT Oncology, Austin
- Texas Oncology, Bedford
- UT Southwest Simmons Cancer Center, Dallas
- и још 2
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 2. 10. 2026. · NCT04585750177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT07189871Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Dallas
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT05867251Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
- M D Anderson Cancer Center, Houston
Тражи се учесник
Узраст 30 и старији · Жене · Ажурирано 25. 9. 2026. · NCT02945579A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- NEXT Oncology - Irving, Irving
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 23. 9. 2026. · NCT06618287Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 21. 9. 2026. · NCT05983432Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Baylor College of Medicine, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 18. 9. 2026. · NCT07340541A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 17. 9. 2026. · NCT07020117First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- NEXT Oncology Austin, Austin
- NEXT Oncology - Dallas, Irving
- NEXT Oncology - San Antonio, San Antonio
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 11. 9. 2026. · NCT06657222Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- UT Health Houston, Houston
Тражи се учесникОпсервациона студија
Узраст од 18 до 99 · Оба пола · Ажурирано 3. 9. 2026. · NCT07211178A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Dallas
- Normunity Investigational Site, Houston
- Normunity Investigational Site, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 18. 8. 2026. · NCT07182149A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Houston Methodist Hospital, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 17. 8. 2026. · NCT04895709Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- START San Antonio, San Antonio
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 8. 2026. · NCT05985655A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Texas Oncology - Central/South Texas, Austin
- Texas Oncology - West Texas, El Paso
- Texas Oncology - Northeast Texas, Flower Mound
- и још 1
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 10. 8. 2026. · NCT06926868Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Uni Of TX MD Anderson Cancer Cntr, Houston
Тражи се учесникФаза 1
Узраст од 18 до 100 · Оба пола · Ажурирано 29. 7. 2026. · NCT06562192A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- UT Southwestern Medical Center - Redbird, Dallas
- Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital, Dallas
- и још 8
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 22. 7. 2026. · NCT05208762Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.